Opus Genetics’ OPGx-LCA5 Gene Therapy Earns FDA RMAT Designation
Opus Genetics, Inc. a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders,…
Read More...
Read More...
